New Risk • May 14
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr7.5m (US$821k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$821k). Market cap is less than US$10m (kr76.9m market cap, or US$8.39m). Board Change • May 11
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Terje Blytt is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 공시 • Mar 21
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 388,240
Price\Range: NOK 5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 348,240
Price\Range: NOK 5
Transaction Features: Rights Offering 공시 • Feb 13
Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 800,000
Price\Range: NOK 5
Transaction Features: Rights Offering New Risk • Dec 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m). New Risk • Dec 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m). Reported Earnings • Dec 01
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). New Risk • Nov 30
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity). 공시 • Nov 22
Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026 Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m). 공시 • May 22
Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. 공시 • May 21
Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. 공시 • Apr 09
Aqua Bio Technology Asa Announces Board Changes Aqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer. 공시 • Apr 04
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,111,975
Price\Range: NOK 0.5
Transaction Features: Rights Offering 공시 • Mar 13
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 48,432,000
Price\Range: NOK 0.5
Transaction Features: Subsequent Direct Listing New Risk • Mar 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m). 공시 • Feb 12
Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025 Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024. 공시 • Jan 21
Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of Directors Aqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment. Board Change • Jan 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 31
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr228.6m market cap, or US$20.2m). Board Change • Dec 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director David Huggins was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Oct 22
Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024 Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021. 공시 • Aug 29
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS. Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors.
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group"). Board Change • Feb 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 02
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Camilla Andersson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Jan 30
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,491,403
Price\Range: NOK 5
Transaction Features: Subsequent Direct Listing 
